Organogenesis PE ratio ORGO

Share price divided by earnings per share over the last twelve months, since 2017.

Today, Oct 23, 2026: n/m; losses over the last year
Last meaningful: 23.4×; May 2026
9-year median: 29.5×
9-year range: 5.2× to 464×
Peer median: 11.3×

Organogenesis has no meaningful PE ratio today: it lost $0.83 a share over the last twelve months, and a PE needs earnings.

It was last meaningful in May 2026, at 23.4×.

On the days it had one over the last 9 years, its median was 29.5×, from 5.2× in Feb 2023 to 464× in Feb 2019.

PE ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	23.4×	20.4×	29.2×
2025	n/m a value too high to mean anything
2024	66.5×	33.3×	81.0×
2023	40.9×	5.2×	40.9×
2022	5.8×	5.6×	18.3×
2021	20.1×	18.9×	176×
2020	n/m a value too high to mean anything
2019	314×	244×	464×
2018	338×	338×	338×
2017	249×	246×	251×

Against its peers

Companies in Drug Manufacturers - General nearest Organogenesis' size, closest first, today.

Company	PE ratio
ORGOOrganogenesis	n/m
NATRNatures Sunshine Products	12.0×
LFVNLifevantage	14.7×
SPROSpero Therapeutics	10.1×
ATNMActinium Pharmaceuticals	4.2×
ARVNArvinas	45.6×
PBYIPuma Biotechnology	21.2×
IRWDIronwood Pharmaceuticals	4.5×
ZVRAZevra Therapeutics	10.5×
CRMDCorMedix	3.7×
COLLCollegium Pharmaceutical	18.5×
Peer median	11.3×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Organogenesis

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.